Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction
Dec 17, 2024 | Anthony A. Bavry, MD,MPH,FACC
Clinical Trial
The goal of the PARAGON-HF trial was to evaluate the neprilysin-angiotension receptor inhibitor sacubitril/valsartan among patients with heart failure with preserved ejection fraction (HFpEF).
Clinical Topics: Heart Failure and Cardiomyopathies, Heart Failure and Cardiac Biomarkers
Keywords: ACC Annual Scientific Session, acc20, AHA19, AHA Annual Scientific Sessions, ESC 19, ESC24, ESC Congress, Heart Failure, Preserved Ejection Fraction, Neprilysin